Showing 1511-1520 of 2526 results for "".
- Celltrion Receives Positive CHMP Opinion for Eylea Biosimilar in the European Unionhttps://modernod.com/news/celltrion-receives-positive-chmp-opinion-for-eylea-biosimilar-in-the-european-union/2482586/Celltrion announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions and recommended marketing authorizations for three biosimilar candidates, including Eydenzelt (CT-P42, aflibercept). Eydenzel
- MediPrint Ophthalmics Unveils Phase 2b Trial Results for Drug-Eluting Contact Lens in Glaucoma Treatmenthttps://modernod.com/news/mediprint-ophthalmics-unveils-phase-2b-trial-results-for-drug-eluting-contact-lens-in-glaucoma-treatment/2482539/MediPrint Ophthalmics announced positive results from its phase 2b clinical trial of its 3D-printed, drug-eluting contact lens LL-BMT1. The results, presented by Ian Ben Gaddie, OD, FAAO, at the Ameri
- Alcon Unveils PRECISION7 1-Week Contact Lens with ACTIV-FLO Technologyhttps://modernod.com/news/alcon-unveils-precision7-one-week-contact-lens-with-activ-flo-technology/2482533/Alcon announced the US launch of PRECISION7, the first contact lens designed for a 1-week replacement cycle. Leveraging the 7-day ACTIV-FLO system, these lenses are designed to deliver up to 16 hours of exceptional comfort and clear vision, even on the seventh day of wear. [1]
- Stanford University Study Finds Ovarian Cancer Drug Can Affect the Eyeshttps://modernod.com/news/stanford-university-study-finds-ovarian-cancer-drug-can-affect-the-eyes/2482510/A study presented at the American Academy of Ophthalmology (AAO) meeting in Chicago found Mirvetuximab soravtansine (Elahere) is associated with corneal toxicity and related vision changes. Mirvetuximab is part of an emerging class of anti-cancer drugs called antibody-drug conjugates. A
- SpyGlass Pharma Unveils Promising 18-Month Data from First-in-Human Study of Glaucoma Drug Delivery Platformhttps://modernod.com/news/spyglass-pharma-unveils-promising-18-month-data-from-first-in-human-study-of-glaucoma-drug-delivery-platform/2482500/SpyGlass Pharma presented 18-month follow-up data today from its first-in-human study of patients with glaucoma or ocular hypertension. The study evaluated the efficacy of the SpyGlass IOL-based drug delivery platform, which was implanted during cataract surgery. The results were shared at Eyecel
- Centricity Vision Unveils Enhancements to ZEPTOLink IOL Positioning System at AAO 2024https://modernod.com/news/centricity-vision-unveils-enhancements-to-zeptolink-iol-positioning-system-at-aao-2024/2482487/Centricity Vision announced platform enhancements for its ZEPTOLink IOL Positioning System designed to reduce treatment time by up to 60%. The enhancements will be highlighted at the American Academy of Ophthalmology (AAO) annual meeting, taking place from October 18-21, 2024, in Chicago.
- Alcon Collaborates with Eye Care Professionals to Identify and Address Unmet Needs in the Contact Lens Industryhttps://modernod.com/news/alcon-collaborates-with-eye-care-professionals-to-identify-and-address-unmet-needs-in-the-contact-lens-industry/2482485/A new Alcon program aims to identify and address current gaps in contact lens offerings by partnering with eye care professionals. With the new Alcon Innovator Program, 20 ‘innovators’ were selected to receive and offer their patients exclusive access to Alcon’s upcoming product
- Cure Blindness Project Unveils Global Expansion Plan on World Sight Dayhttps://modernod.com/news/cure-blindness-project-unveils-global-expansion-plan-on-world-sight-day/2482471/In honor of World Sight Day on October 10, the non-profit Cure Blindness Project announced an expansion plan that will extend its sight-restoring services to six new countries: Burundi, Democratic Republic of the Congo, Liberia, Pakistan, Paraguay, and Zambia. This move marks the organi
- Lumibird Unveils Omnicad Imaging Platform for Ocular Surface Diseasehttps://modernod.com/news/lumibird-unveils-omnicad-imaging-platform-for-ocular-surface-disease/2482453/Lumibird Medical announced the launch of the Omnicad, an imaging platform equipped with integrated AI algorithms designed to aid in the diagnosis of ocular surface disease (OSD). The device, exclusively available in the US market, aims to address the needs of optometrists and ophthalmol
- New Study on AI-Driven Solutions for Diabetic Eye Disease Testing in Underserved Populations Publishedhttps://modernod.com/news/new-study-on-ai-driven-solutions-for-diabetic-eye-disease-testing-in-underserved-populations-published/2482441/Michael D. Abramoff, MD, PhD, founder and executive chairman of Digital Diagnostics, and the creator of the LumineticsCore AI system for diagnosing diabetic retinopathy, has co-authored a study exploring the potential of autono